Junshi Biosciences Doses First Patient in Phase 3 Trial of JS203 for Lymphoma

By Public Technologies
  • Junshi Biosciences announced first-patient dosing in its Phase 3 JS203 lymphoma trial on Oct. 23, 2026.
  • The trial compares JS203 plus chemotherapy with rituximab plus chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.
  • This first registrational study for JS203 plans to enroll 282 patients, with overall survival as the primary endpoint.
  • Previously reported Phase 1 results showed tumor responses, including complete responses, with sustained relief and a manageable safety profile.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610232330OMX_____CNEWS_EN_GNW9852512_en) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.